Aridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business Update
LOS GATOS, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTCQB: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today reported financial and corporate results for its third quarter ended September 30, 2023.
- OTCQB companies must be current in their financial reporting and undergo an annual verification and management certification process.
- We remain optimistic of successful outcomes from these efforts in the coming months,” commented Vu Truong, Ph.D., Chief Executive Officer of Aridis Pharmaceuticals.
- Due to fair value option valuation of our notes payable, there was no interest expense recorded during the third quarter of 2023.
- Other Income: Other income increased to $26,000 for the quarter ended September 30, 2023, compared to approximately $23,000 for the quarter ended September 30, 2022.